Premium
UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111)
Author(s) -
Tam C.S.,
Wang M.,
Simpson D.,
Opat S.,
Cull G.,
Munoz J.,
Phillips T.J.,
Kim W.,
Atwal S.,
Wei R.,
Huang J.,
Elstrom R.,
Trotman J.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.55_2630
Subject(s) - medicine , ibrutinib , bruton's tyrosine kinase , adverse effect , mantle cell lymphoma , progressive disease , neutropenia , gastroenterology , phases of clinical research , oncology , surgery , clinical trial , lymphoma , tyrosine kinase , chronic lymphocytic leukemia , toxicity , chemotherapy , leukemia , receptor
UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111) C.S. Tam | M. Wang | D. Simpson | S. Opat | G. Cull | J. Munoz | T.J. Phillips | W. Kim | S. Atwal | R. Wei | J. Huang | R. Elstrom | J. Trotman Department of Haematology, Peter MacCallum Cancer Centre, St. Vincent’s Hospital, University of Melbourne, Melbourne, Victoria, Australia; Department of Lymphoma & Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, United States; Waitemata DHB Haematology Service, North Shore Hospital, Auckland, New Zealand; Clinical Haematology, Monash Health, Monash University, Clayton, Victoria, Australia; Department of Haematology, Sir Charles Gairdner Hospital, University of Western Australia, Perth, WA, Australia; Hematology-Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, United States; Michigan Medicine Hematology Clinic, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Research and Development Center, BeiGene (Beijing) Co., Ltd, Beijing, China; BeiGene USA, Inc., San Mateo, United States; Department of Haematology, Concord Repatriation Hospital, The University of Sydney, Concord, NSW, Australia